Statins and the risks of stroke recurrence and death after ischemic stroke: The Fukuoka Stroke Registry

Noriko Makihara, Masahiro Kamouchi, Jun Hata, Ryu Matsuo, Tetsuro Ago, Junya Kuroda, Takahiro Kuwashiro, Hiroshi Sugimori, Takanari Kitazono, Takao Ishitsuka, Shigeru Fujimoto, Setsuro Ibayashi, Kenji Kusuda, Shuji Arakawa, Katsumi Irie, Kenichiro Fujii, Yoshiyuki Wakugawa, Yasushi Okada, Masahiro Yasaka, Tetsuhiko NagaoHiroaki Ooboshi, Tsuyoshi Omae, Kazunori Toyoda, Hiroshi Nakane, Kenji Fukuda, Yoshihisa Fukushima, Kinya Tamaki, Seizo Sadoshima

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

Background and purpose: The findings of recent clinical trials suggest that treatment with high-dose statins reduces the risk of stroke recurrence. However, the doses approved in Japan are much lower than those in the previous studies. This study aimed to elucidate whether prescribed doses of statins reduce the risks of cerebrovascular events (CVEs: stroke recurrence or transient ischemic attack) and all-cause mortality in a cohort of Japanese patients with first-ever ischemic stroke. Methods: The 2822 eligible patients registered in the Fukuoka Stroke Registry with first-ever acute ischemic stroke from June 2007 to February 2011 were classified into statin users (n=993) and non-users (n=1829) at discharge, and followed up until March 2012. We assessed the cumulative risks of CVE and all-cause mortality by the Kaplan-Meier method, and calculated hazard ratios (HRs) and 95% confidential intervals (CIs) using the Cox proportional hazards model. Results: During the follow-up time (median, 2.0 years), 305 patients had CVEs and 345 died. The cumulative risks of CVE and death after 4 years were significantly lower in statin users than in non-users (13.8% versus 19.5%, P=0.005 for CVE; 11.8% versus 21.7%, P<0.001 for death). After adjusting for multiple confounding factors, statin treatment significantly reduced the risks of CVE (HR, 0.70; 95% CI, 0.53 to 0.92; P=0.011) and all-cause mortality (HR, 0.67; 95% CI, 0.50 to 0.89; P=0.006). Conclusions: Our findings suggest that low-dose statin may reduce the risks of CVE and death in Japanese patients with acute ischemic stroke.

元の言語英語
ページ(範囲)211-215
ページ数5
ジャーナルAtherosclerosis
231
発行部数2
DOI
出版物ステータス出版済み - 12 1 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Registries
Stroke
Recurrence
Mortality
Transient Ischemic Attack
Proportional Hazards Models
Japan
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

これを引用

Statins and the risks of stroke recurrence and death after ischemic stroke : The Fukuoka Stroke Registry. / Makihara, Noriko; Kamouchi, Masahiro; Hata, Jun; Matsuo, Ryu; Ago, Tetsuro; Kuroda, Junya; Kuwashiro, Takahiro; Sugimori, Hiroshi; Kitazono, Takanari; Ishitsuka, Takao; Fujimoto, Shigeru; Ibayashi, Setsuro; Kusuda, Kenji; Arakawa, Shuji; Irie, Katsumi; Fujii, Kenichiro; Wakugawa, Yoshiyuki; Okada, Yasushi; Yasaka, Masahiro; Nagao, Tetsuhiko; Ooboshi, Hiroaki; Omae, Tsuyoshi; Toyoda, Kazunori; Nakane, Hiroshi; Fukuda, Kenji; Fukushima, Yoshihisa; Tamaki, Kinya; Sadoshima, Seizo.

:: Atherosclerosis, 巻 231, 番号 2, 01.12.2013, p. 211-215.

研究成果: ジャーナルへの寄稿記事

Makihara, N, Kamouchi, M, Hata, J, Matsuo, R, Ago, T, Kuroda, J, Kuwashiro, T, Sugimori, H, Kitazono, T, Ishitsuka, T, Fujimoto, S, Ibayashi, S, Kusuda, K, Arakawa, S, Irie, K, Fujii, K, Wakugawa, Y, Okada, Y, Yasaka, M, Nagao, T, Ooboshi, H, Omae, T, Toyoda, K, Nakane, H, Fukuda, K, Fukushima, Y, Tamaki, K & Sadoshima, S 2013, 'Statins and the risks of stroke recurrence and death after ischemic stroke: The Fukuoka Stroke Registry', Atherosclerosis, 巻. 231, 番号 2, pp. 211-215. https://doi.org/10.1016/j.atherosclerosis.2013.09.017
Makihara, Noriko ; Kamouchi, Masahiro ; Hata, Jun ; Matsuo, Ryu ; Ago, Tetsuro ; Kuroda, Junya ; Kuwashiro, Takahiro ; Sugimori, Hiroshi ; Kitazono, Takanari ; Ishitsuka, Takao ; Fujimoto, Shigeru ; Ibayashi, Setsuro ; Kusuda, Kenji ; Arakawa, Shuji ; Irie, Katsumi ; Fujii, Kenichiro ; Wakugawa, Yoshiyuki ; Okada, Yasushi ; Yasaka, Masahiro ; Nagao, Tetsuhiko ; Ooboshi, Hiroaki ; Omae, Tsuyoshi ; Toyoda, Kazunori ; Nakane, Hiroshi ; Fukuda, Kenji ; Fukushima, Yoshihisa ; Tamaki, Kinya ; Sadoshima, Seizo. / Statins and the risks of stroke recurrence and death after ischemic stroke : The Fukuoka Stroke Registry. :: Atherosclerosis. 2013 ; 巻 231, 番号 2. pp. 211-215.
@article{7dd0c3a1dac34cc385a97f8eec4b6bd5,
title = "Statins and the risks of stroke recurrence and death after ischemic stroke: The Fukuoka Stroke Registry",
abstract = "Background and purpose: The findings of recent clinical trials suggest that treatment with high-dose statins reduces the risk of stroke recurrence. However, the doses approved in Japan are much lower than those in the previous studies. This study aimed to elucidate whether prescribed doses of statins reduce the risks of cerebrovascular events (CVEs: stroke recurrence or transient ischemic attack) and all-cause mortality in a cohort of Japanese patients with first-ever ischemic stroke. Methods: The 2822 eligible patients registered in the Fukuoka Stroke Registry with first-ever acute ischemic stroke from June 2007 to February 2011 were classified into statin users (n=993) and non-users (n=1829) at discharge, and followed up until March 2012. We assessed the cumulative risks of CVE and all-cause mortality by the Kaplan-Meier method, and calculated hazard ratios (HRs) and 95{\%} confidential intervals (CIs) using the Cox proportional hazards model. Results: During the follow-up time (median, 2.0 years), 305 patients had CVEs and 345 died. The cumulative risks of CVE and death after 4 years were significantly lower in statin users than in non-users (13.8{\%} versus 19.5{\%}, P=0.005 for CVE; 11.8{\%} versus 21.7{\%}, P<0.001 for death). After adjusting for multiple confounding factors, statin treatment significantly reduced the risks of CVE (HR, 0.70; 95{\%} CI, 0.53 to 0.92; P=0.011) and all-cause mortality (HR, 0.67; 95{\%} CI, 0.50 to 0.89; P=0.006). Conclusions: Our findings suggest that low-dose statin may reduce the risks of CVE and death in Japanese patients with acute ischemic stroke.",
author = "Noriko Makihara and Masahiro Kamouchi and Jun Hata and Ryu Matsuo and Tetsuro Ago and Junya Kuroda and Takahiro Kuwashiro and Hiroshi Sugimori and Takanari Kitazono and Takao Ishitsuka and Shigeru Fujimoto and Setsuro Ibayashi and Kenji Kusuda and Shuji Arakawa and Katsumi Irie and Kenichiro Fujii and Yoshiyuki Wakugawa and Yasushi Okada and Masahiro Yasaka and Tetsuhiko Nagao and Hiroaki Ooboshi and Tsuyoshi Omae and Kazunori Toyoda and Hiroshi Nakane and Kenji Fukuda and Yoshihisa Fukushima and Kinya Tamaki and Seizo Sadoshima",
year = "2013",
month = "12",
day = "1",
doi = "10.1016/j.atherosclerosis.2013.09.017",
language = "English",
volume = "231",
pages = "211--215",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Statins and the risks of stroke recurrence and death after ischemic stroke

T2 - The Fukuoka Stroke Registry

AU - Makihara, Noriko

AU - Kamouchi, Masahiro

AU - Hata, Jun

AU - Matsuo, Ryu

AU - Ago, Tetsuro

AU - Kuroda, Junya

AU - Kuwashiro, Takahiro

AU - Sugimori, Hiroshi

AU - Kitazono, Takanari

AU - Ishitsuka, Takao

AU - Fujimoto, Shigeru

AU - Ibayashi, Setsuro

AU - Kusuda, Kenji

AU - Arakawa, Shuji

AU - Irie, Katsumi

AU - Fujii, Kenichiro

AU - Wakugawa, Yoshiyuki

AU - Okada, Yasushi

AU - Yasaka, Masahiro

AU - Nagao, Tetsuhiko

AU - Ooboshi, Hiroaki

AU - Omae, Tsuyoshi

AU - Toyoda, Kazunori

AU - Nakane, Hiroshi

AU - Fukuda, Kenji

AU - Fukushima, Yoshihisa

AU - Tamaki, Kinya

AU - Sadoshima, Seizo

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Background and purpose: The findings of recent clinical trials suggest that treatment with high-dose statins reduces the risk of stroke recurrence. However, the doses approved in Japan are much lower than those in the previous studies. This study aimed to elucidate whether prescribed doses of statins reduce the risks of cerebrovascular events (CVEs: stroke recurrence or transient ischemic attack) and all-cause mortality in a cohort of Japanese patients with first-ever ischemic stroke. Methods: The 2822 eligible patients registered in the Fukuoka Stroke Registry with first-ever acute ischemic stroke from June 2007 to February 2011 were classified into statin users (n=993) and non-users (n=1829) at discharge, and followed up until March 2012. We assessed the cumulative risks of CVE and all-cause mortality by the Kaplan-Meier method, and calculated hazard ratios (HRs) and 95% confidential intervals (CIs) using the Cox proportional hazards model. Results: During the follow-up time (median, 2.0 years), 305 patients had CVEs and 345 died. The cumulative risks of CVE and death after 4 years were significantly lower in statin users than in non-users (13.8% versus 19.5%, P=0.005 for CVE; 11.8% versus 21.7%, P<0.001 for death). After adjusting for multiple confounding factors, statin treatment significantly reduced the risks of CVE (HR, 0.70; 95% CI, 0.53 to 0.92; P=0.011) and all-cause mortality (HR, 0.67; 95% CI, 0.50 to 0.89; P=0.006). Conclusions: Our findings suggest that low-dose statin may reduce the risks of CVE and death in Japanese patients with acute ischemic stroke.

AB - Background and purpose: The findings of recent clinical trials suggest that treatment with high-dose statins reduces the risk of stroke recurrence. However, the doses approved in Japan are much lower than those in the previous studies. This study aimed to elucidate whether prescribed doses of statins reduce the risks of cerebrovascular events (CVEs: stroke recurrence or transient ischemic attack) and all-cause mortality in a cohort of Japanese patients with first-ever ischemic stroke. Methods: The 2822 eligible patients registered in the Fukuoka Stroke Registry with first-ever acute ischemic stroke from June 2007 to February 2011 were classified into statin users (n=993) and non-users (n=1829) at discharge, and followed up until March 2012. We assessed the cumulative risks of CVE and all-cause mortality by the Kaplan-Meier method, and calculated hazard ratios (HRs) and 95% confidential intervals (CIs) using the Cox proportional hazards model. Results: During the follow-up time (median, 2.0 years), 305 patients had CVEs and 345 died. The cumulative risks of CVE and death after 4 years were significantly lower in statin users than in non-users (13.8% versus 19.5%, P=0.005 for CVE; 11.8% versus 21.7%, P<0.001 for death). After adjusting for multiple confounding factors, statin treatment significantly reduced the risks of CVE (HR, 0.70; 95% CI, 0.53 to 0.92; P=0.011) and all-cause mortality (HR, 0.67; 95% CI, 0.50 to 0.89; P=0.006). Conclusions: Our findings suggest that low-dose statin may reduce the risks of CVE and death in Japanese patients with acute ischemic stroke.

UR - http://www.scopus.com/inward/record.url?scp=84888112150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888112150&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2013.09.017

DO - 10.1016/j.atherosclerosis.2013.09.017

M3 - Article

C2 - 24267228

AN - SCOPUS:84888112150

VL - 231

SP - 211

EP - 215

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -